Petredis Investment Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$377K Sell
1,040
-150
-13% -$51.3K 0.03% 105
2026
Q1
$419K Sell
1,190
-16
-1% -$5.7K 0.03% 101
2025
Q4
$395K Sell
1,206
-200
-14% -$63.4K 0.03% 101
2025
Q3
$397K Sell
1,406
-100
-7% -$29K 0.03% 103
2025
Q2
$420K Hold
1,506
0.04% 101
2025
Q1
$469K Hold
1,506
0.05% 97
2024
Q4
$393K Sell
1,506
-50
-3% -$14.8K 0.04% 93
2024
Q3
$501K Sell
1,556
-7
-0.4% -$2.29K 0.05% 94
2024
Q2
$488K Buy
1,563
+23
+1% +$6.76K 0.05% 95
2024
Q1
$438K Hold
1,540
0.05% 95
2023
Q4
$444K Hold
1,540
0.06% 93
2023
Q3
$414K Hold
1,540
0.06% 90
2023
Q2
$342K Hold
1,540
0.05% 93
2023
Q1
$372K Hold
1,540
0.06% 90
2022
Q4
$404K Buy
+1,540
New +$413K 0.07% 88

Other funds holding AMGN

Petredis Investment Advisors's AMGN Position: Q2 2026 in Review

Petredis Investment Advisors reduced its Amgen (AMGN) stake by 13% in Q2 2026, selling an estimated $51.3K and leaving 1,040 shares worth $377K. The position accounts for 0.03% of the portfolio, ranked #105.

Petredis Investment Advisors first reported a position in AMGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $501K in Q3 2024. 659 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Petredis Investment Advisors held 1,040 shares of Amgen worth $377K as of Q2 2026.
  • Petredis Investment Advisors sold 150 Amgen shares in Q2 2026, an estimated $51.3K.
  • Amgen made up 0.03% of Petredis Investment Advisors's portfolio in Q2 2026, its #105 holding.
  • Petredis Investment Advisors first reported a position in Amgen in Q4 2022 and has held it in 15 quarters since.
  • Petredis Investment Advisors's Amgen position peaked at $501K in Q3 2024.
  • 659 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Petredis Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.